WO2023035867A8 - 枸杞糖肽在制备预防和/或治疗肌萎缩侧索硬化的药物中的应用 - Google Patents
枸杞糖肽在制备预防和/或治疗肌萎缩侧索硬化的药物中的应用 Download PDFInfo
- Publication number
- WO2023035867A8 WO2023035867A8 PCT/CN2022/112447 CN2022112447W WO2023035867A8 WO 2023035867 A8 WO2023035867 A8 WO 2023035867A8 CN 2022112447 W CN2022112447 W CN 2022112447W WO 2023035867 A8 WO2023035867 A8 WO 2023035867A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- goji
- glycopeptide
- drug
- preventing
- preparation
- Prior art date
Links
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 title abstract 4
- 102000002068 Glycopeptides Human genes 0.000 title abstract 4
- 108010015899 Glycopeptides Proteins 0.000 title abstract 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 3
- 238000011831 SOD1-G93A transgenic mouse Methods 0.000 abstract 4
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 210000005230 lumbar spinal cord Anatomy 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及生物医药领域，特别涉及枸杞糖肽在制备预防和/或治疗肌萎缩侧索硬化的药物中的应用。实验结果表明，枸杞糖肽在制备预防和/或治疗肌萎缩侧索硬化的药物中的应用。具体的，枸杞糖肽减缓SOD1G93A转基因小鼠体重下降，延长SOD1G93A转基因小鼠的生存周期，延长SOD1G93A转基因小鼠的病程，下调SOD1G93A转基因小鼠腰段脊髓炎症因子的相对表达量。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202280006961.6A CN116390740B (zh) | 2021-09-08 | 2022-08-15 | 枸杞糖肽在制备预防和/或治疗肌萎缩侧索硬化的药物中的应用 |
| US18/236,085 US20240139281A1 (en) | 2021-09-08 | 2023-08-21 | Use of goji glycopeptide in preparation of drug for preventing and/or treating amyotrophic lateral sclerosis |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111047838.2A CN113842449B (zh) | 2021-09-08 | 2021-09-08 | 枸杞糖肽在制备预防和/或治疗肌萎缩侧索硬化的药物中的应用 |
| CN202111047838.2 | 2021-09-08 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US18/236,085 Continuation-In-Part US20240139281A1 (en) | 2021-09-08 | 2023-08-21 | Use of goji glycopeptide in preparation of drug for preventing and/or treating amyotrophic lateral sclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2023035867A1 WO2023035867A1 (zh) | 2023-03-16 |
| WO2023035867A8 true WO2023035867A8 (zh) | 2023-08-10 |
Family
ID=78973403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2022/112447 WO2023035867A1 (zh) | 2021-09-08 | 2022-08-15 | 枸杞糖肽在制备预防和/或治疗肌萎缩侧索硬化的药物中的应用 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20240139281A1 (zh) |
| CN (2) | CN113842449B (zh) |
| WO (1) | WO2023035867A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113842449B (zh) * | 2021-09-08 | 2024-02-23 | 乐卫东 | 枸杞糖肽在制备预防和/或治疗肌萎缩侧索硬化的药物中的应用 |
| CN114558108A (zh) * | 2022-01-20 | 2022-05-31 | 宁夏杞肽科技有限公司 | 枸杞糖肽在制备缓解神经病理性疼痛的药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1172699C (zh) * | 2002-05-22 | 2004-10-27 | 阎洪臣 | 一种治疗脊髓空洞症的中药制剂 |
| WO2005007676A2 (en) * | 2003-07-10 | 2005-01-27 | Rajadhyaksha V J | Glycopeptides for the treatment of als and other metabolic and autoimmune disorders |
| WO2009097512A1 (en) * | 2008-02-01 | 2009-08-06 | Innovative Drug Discovery Inc. | Herbal pharmaceutical compositions to treat inflammation and inflammation associated conditions and diseases |
| JP2011121949A (ja) * | 2009-12-14 | 2011-06-23 | Kyoto Univ | 筋萎縮性側索硬化症の予防および治療用医薬組成物 |
| KR20210014109A (ko) * | 2018-05-10 | 2021-02-08 | 더 메서디스트 하스피틀 | 질환의 예후와 관리 방법 |
| CN109172692A (zh) * | 2018-11-02 | 2019-01-11 | 杨京润 | 一种抗压力抗氧化防治肌肉萎缩的药物及其制备方法 |
| CN113842449B (zh) * | 2021-09-08 | 2024-02-23 | 乐卫东 | 枸杞糖肽在制备预防和/或治疗肌萎缩侧索硬化的药物中的应用 |
-
2021
- 2021-09-08 CN CN202111047838.2A patent/CN113842449B/zh active Active
-
2022
- 2022-08-15 WO PCT/CN2022/112447 patent/WO2023035867A1/zh active Application Filing
- 2022-08-15 CN CN202280006961.6A patent/CN116390740B/zh active Active
-
2023
- 2023-08-21 US US18/236,085 patent/US20240139281A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN116390740B (zh) | 2024-07-09 |
| CN116390740A (zh) | 2023-07-04 |
| WO2023035867A1 (zh) | 2023-03-16 |
| CN113842449A (zh) | 2021-12-28 |
| CN113842449B (zh) | 2024-02-23 |
| US20240139281A1 (en) | 2024-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2023035867A8 (zh) | 枸杞糖肽在制备预防和/或治疗肌萎缩侧索硬化的药物中的应用 | |
| MX2013005250A (es) | Polipeptidos derivados de la il-2 con actividad agonista para la terapia del cancer e infecciones cronicas. | |
| PH12020500309A1 (en) | Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use | |
| EP4317185A3 (en) | Fully-human post-translationally modified antibody therapeutics | |
| JOP20200156A1 (ar) | إيسكيتامين لعلاج الاكتئاب | |
| MY172185A (en) | Artificial tears and therapeutic uses | |
| RU2020123728A (ru) | Композиции гиалуроновой кислоты с высокоэластичными свойствами и способы их применения | |
| NZ702967A (en) | Diclofenac formulations | |
| AR088585A1 (es) | Un medicamento para tratar la enfermedad del ojo anterior | |
| MX2021007434A (es) | Peptidos de colageno producidos de forma sintetica y recombinante con eficacia biologica. | |
| CN109475632A (zh) | 癌免疫佐剂 | |
| MX2019012086A (es) | Composiciones y métodos para tratar o prevenir trastornos relacionados con la permeabilidad intestinal. | |
| NZ602479A (en) | Pharmaceutical composition for the treatment of dry eye and/or corneal and conjunctival lesion | |
| CL2022000786A1 (es) | Metodos de tratamiento para modificar la hemodinamica | |
| MX338323B (es) | Formulacion topica oftalmica de peptidos. | |
| CL2020001426A1 (es) | Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo. | |
| Zhou et al. | Progress of targeting transforming growth factor-β1 small interfering RNA in liver fibrosis | |
| MX2021011183A (es) | Fitoecdisonas y los derivados de las mismas para su uso en el tratamiento de la alteracion de la funcion respiratoria. | |
| WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
| EA202090966A1 (ru) | МОНОКЛОНАЛЬНЫЕ АНТИ-TrkB АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| WO2019055776A3 (en) | Compositions and methods for treatment of diseases involving cxcl1 function | |
| MX2015006779A (es) | Proteina slurp-1 para usarse en el tratamiento de enfermedades oculares. | |
| MX2023011508A (es) | Dosificacion y administracion de l-asparaginasa recombinante. | |
| MX2022012544A (es) | Liberacion dirigida de un inhibidor de mir-21 a macrofagos para el tratamiento de la fibrosis pulmonar. | |
| MX2022006523A (es) | Composicion que comprende budesonida para uso oftalmico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22866341 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 22866341 Country of ref document: EP Kind code of ref document: A1 |